What is Cradle?
Founded in 2021, Cradle leverages powerful prediction algorithms and AI-driven design suggestions to assist biologists in creating improved proteins with unprecedented speed. The company's technology aims to revolutionize protein engineering by providing tools that accelerate research and development cycles, enabling faster discovery and optimization of protein functions for various applications. Cradle's platform is positioned to be a critical asset for research institutions and companies operating in the life sciences, synthetic biology, and pharmaceutical industries.
How much funding has Cradle raised?
Cradle has raised a total of $102.7M across 3 funding rounds:
Angel/Seed
$5.7M
Series A
$24M
Series B
$73M
Angel/Seed (2022): $5.7M with participation from Index Ventures and Kindred Capital
Series A (2023): $24M led by Index Ventures and Kindred Capital
Series B (2024): $73M supported by IVP, Index Ventures, and Kindred Capital
Key Investors in Cradle
Index Ventures
Index Ventures is a venture firm investing in the next generation of entrepreneurs from seed to IPO, partnering with founders with bold dreams to build enduring companies. They have offices in San Francisco & London and invest globally.
IVP
IVP (Institutional Venture Partners) is a Menlo Park-based later-stage venture capital firm that invests in high-growth technology companies, primarily at Series B and beyond, across consumer, enterprise, and fintech.
Kindred Capital
Kindred Capital is a venture capital firm founded in 2015, headquartered in London, England, offering equitable venture and investment thesis.
What's next for Cradle?
With the recent infusion of $73M in a major strategic investment, Cradle is poised for accelerated expansion and further development of its AI-powered protein design platform. This substantial backing, part of its overall $102.7M in capital, suggests a focus on scaling operations, enhancing its technological capabilities, and potentially broadening its market reach. The company's trajectory indicates a move towards solidifying its position as a leader in AI-driven biotechnology solutions, likely investing in R&D to maintain its competitive edge and exploring new applications for its core technology.
See full Cradle company page
